<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635738</url>
  </required_header>
  <id_info>
    <org_study_id>TH-IRB-10-14</org_study_id>
    <nct_id>NCT01635738</nct_id>
  </id_info>
  <brief_title>Probiotics and Allergic Diseases</brief_title>
  <acronym>probiotics</acronym>
  <official_title>Probiotics and Allergic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenMont Biotech Incorporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GenMont Biotech Incorporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many studies had demonstrated that probiotics could be applied in the prevention and adjuvant
      treatment for allergic diseases. In this study, we investigate the effects of Lactobacillus
      paracasei GMNL-133(LP), Lactobacillus fermentum GM-090 (LF), and Lactobacillus paracasei
      GMNL-133(LP) with Lactobacillus fermentum GM-090 (LF) combination products used for adjuvant
      treatment of atopic dermatitis and asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose: To investigate if Lactobacillus paracasei GMNL-133(LP), Lactobacillus
      fermentum GM-090(LF), Lactobacillus paracasei GMNL-133 (LP) with Lactobacillus fermentum
      GM-090 (LF) combination products could be used for the adjuvant treatment of atopic
      dermatitis and asthma.

      The Secondary Objective: To investigate whether probiotics consumption improve the quality of
      life and allergic symptoms to different people with Lactobacillus paracasei GMNL-133 (LP),
      Lactobacillus fermentum GM-090 (LF) and Lactobacillus paracasei GMNL-133(LP) and
      Lactobacillus fermentum GM-090 (LF) combination products.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effects of probiotics in improving life quality and symptomatic severity</measure>
    <time_frame>2 years</time_frame>
    <description>Atopic dermatitis
Primary Endpoints:
SCORAD score, Children's Dermatology Life Quality Index (CDLQI), and Dermatitis Family Impact Questionnaire
Asthma
Primary Endpoints:
GINA guideline asthma severity ( step up or step down) ACT, PAQLQ, PACQLQ, PASS Questionnaire
Allergic Rhinitis
Primary Endpoints:
ARIA allergic rhinitis severity PRQLQ, NTSS Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effects of probiotics on biomakers and other symptom relief</measure>
    <time_frame>2 years</time_frame>
    <description>Atopic dermatitis:
Decrease topical steroid and oral antihistamine use, changes of skin prick test severity, effect persistency after discontinuing Lactobacillus paracasei GMNL-133, Lactobacillus fermentum GM-090 or the composition of Lactobacillus paracasei GMNL-133 and Lactobacillus fermentum GM-090 intake, changes of cytokine and IgE, urine EPX, 8-ohdg biomarkers.
Comparison of Probiotic group (LP, LF and LP+LF) and placebo group
Asthma:
Peak flow lung function, the changes of skin prick test severity, effect persistency after discontinuing probiotics, ISAAC questionnaire, use of rescue medication, unscheduled visit to emergency unit, changes of cytokine and IgE, urine EPX, 8-ohdg biomarkers Comparison of Probiotic group (LP, LF and LP+LF) and placebo group
Allergic Rhinitis :
Changes of skin prick test severity, effect persistency after discontinuing probiotics, ISAAC questionnaire, use of rescue medication, changes of cytokine and IgE, urine EPX, 8-ohdg biomarkers.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>LP GMNL-133 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm: LP GMNL-133 group One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LF GM-090 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LP GMNL-133+LF GM-090 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One capsule with 2x10^9 (cfu) LP GMNL-133+ 2x10^9 (cfu)LF GM-090, once daily, PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LP GMNL-133 capsule</intervention_name>
    <description>One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO</description>
    <arm_group_label>LP GMNL-133 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LF GM-090 capsule</intervention_name>
    <description>Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO</description>
    <arm_group_label>LF GM-090 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LP GMNL-133 +LF GM-090 capsule</intervention_name>
    <description>One capsule with 4x10^9 (cfu) LP GMNL-133 +LF GM-090, once daily, PO</description>
    <arm_group_label>LP GMNL-133+LF GM-090 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 1 year old and 18 years old,

          2. AD cases fulfill the diagnostic criteria by Hannifin and Rajka.

          3. Atopy as shown by at least one positive skin test (weal size ≧ 3mm) or one positive
             MAST (RAST) (IgE ≧ 0.7 kU/L) test to any common food or environmental allergens.

        Exclusion Criteria:

          1. Systematic corticosteroid, immunosuppressive therapy, or antimycotics treatment during
             the 4 weeks, antihistamines, and singulair during the 7 days before enrollment

          2. Probiotic preparations used within 2 weeks before entering the study

          3. Use of antibiotics now or other oral medications that will interfere the results

          4. If they had immune deficiency disease or other major medical problems

          5. If they had participated in another clinical study during the past month.

          6. Subjects are undergoing desensitization therapy within 3 months prior to the screening
             period.

          7. Subjects have participated investigational drug trial within 4 weeks before entering
             this study.

          8. Subjects are pregnant, lactating or planning to become pregnant.

          9. Subjects with any other serious diseases considered by the investigator that could
             interfere with the performance of SCORAD score result.

         10. Subjects who is lack of physical integrity of gastrointestinal tract, or malabsorption
             syndrome, or inability to take oral medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I-Jen Wang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Taipei Hospital, Department of Health, Taiwan, R.O.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Hospital, Department of Health, Taiwan, R.O.C.</name>
      <address>
        <city>New Taipei City</city>
        <zip>24213</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Hong HJ, Kim E, Cho D, Kim TS. Differential suppression of heat-killed lactobacilli isolated from kimchi, a Korean traditional food, on airway hyper-responsiveness in mice. J Clin Immunol. 2010 May;30(3):449-58. doi: 10.1007/s10875-010-9375-8. Epub 2010 Mar 5.</citation>
    <PMID>20204477</PMID>
  </results_reference>
  <results_reference>
    <citation>Yao TC, Chang CJ, Hsu YH, Huang JL. Probiotics for allergic diseases: realities and myths. Pediatr Allergy Immunol. 2010 Sep;21(6):900-19. doi: 10.1111/j.1399-3038.2009.00955.x. Epub 2009 Dec 9. Review.</citation>
    <PMID>20003066</PMID>
  </results_reference>
  <results_reference>
    <citation>Park CW, Youn M, Jung YM, Kim H, Jeong Y, Lee HK, Kim HO, Lee I, Lee SW, Kang KH, Park YH. New functional probiotic Lactobacillus sakei probio 65 alleviates atopic symptoms in the mouse. J Med Food. 2008 Sep;11(3):405-12. doi: 10.1089/jmf.2007.0144.</citation>
    <PMID>18800885</PMID>
  </results_reference>
  <results_reference>
    <citation>Peng GC, Hsu CH. The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatr Allergy Immunol. 2005 Aug;16(5):433-8.</citation>
    <PMID>16101937</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang MF, Lin HC, Wang YY, Hsu CH. Treatment of perennial allergic rhinitis with lactic acid bacteria. Pediatr Allergy Immunol. 2004 Apr;15(2):152-8.</citation>
    <PMID>15059192</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2012</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Lactobacillus paracasei GMNL-133</keyword>
  <keyword>Lactobacillus fermentum GM-090</keyword>
  <keyword>Atopic dermatitis</keyword>
  <keyword>Asthma</keyword>
  <keyword>Lactobacillus paracasei</keyword>
  <keyword>Lactobacillus fermentum</keyword>
  <keyword>efficacy and safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

